Treatment of Depression and Anxiety in Perimenopause

First-Line Treatment Options

Cognitive behavioral therapy (CBT) is recommended as first-line treatment for depression and anxiety in perimenopausal women, with efficacy comparable to second-generation antidepressants, according to the American College of Physicians 1
CBT should be provided by qualified therapists in individual sessions, particularly for anxiety disorders, as suggested by the American Psychological Association 1
Mental health professionals should regularly assess treatment response (e.g., at pretreatment, 4 weeks, 8 weeks, and end of treatment), as recommended by the National Comprehensive Cancer Network 2
SSRIs and SNRIs are recommended as first-line pharmacological treatments for both depression and anxiety, according to the American College of Obstetricians and Gynecologists 1, 2
For patients with symptoms of both depression and anxiety, treatment of depressive symptoms should be prioritized, or a unified protocol combining CBT for both conditions may be used, as suggested by the Journal of Clinical Oncology 2

When prescribing SSRIs, avoid potent CYP2D6 inhibitors (particularly paroxetine and fluoxetine) in women taking tamoxifen, as they may interfere with tamoxifen metabolism, according to the National Comprehensive Cancer Network 3
Venlafaxine (an SNRI) is effective for managing both mood symptoms and hot flashes, as reported by the Journal of the National Comprehensive Cancer Network 3
Mild CYP2D6 inhibitors such as citalopram, escitalopram, sertraline, and venlafaxine have minimal effect on tamoxifen metabolism and are preferred options, according to the National Comprehensive Cancer Network 3

SSRIs/SNRIs can help manage both mood symptoms and hot flashes, though they are generally less effective than estrogen for vasomotor symptom relief, as reported by the Annals of Oncology 4
Gabapentin and pregabalin have shown efficacy for vasomotor symptoms in both general population and female cancer survivors, according to the Annals of Oncology 4

Nonhormonal options are preferred as first-line therapy for cancer survivors with menopausal symptoms affecting quality of life, as recommended by the National Comprehensive Cancer Network 5
Low-dose antidepressants (SSRIs/SNRIs) have shown efficacy in reducing vasomotor symptoms in breast cancer survivors, according to the National Comprehensive Cancer Network 5
Paroxetine at 7.5mg daily has been shown to reduce frequency and severity of vasomotor symptoms in a randomized, double-blind, placebo-controlled study of gynecologic cancer survivors, as reported by the National Comprehensive Cancer Network 5

Clinicians should regularly assess treatment response using standardized validated instruments at 4 and 8 weeks, as recommended by the Journal of Clinical Oncology 2
If symptoms are stable or worsening, the treatment plan should be reevaluated and revised, according to the Journal of Clinical Oncology 2
For pharmacological treatment, monitor symptom relief, side effects, and patient satisfaction, as suggested by the Journal of Clinical Oncology 2